TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10630940

Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide in an oral base 0.1%
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide gel no. 1
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide gel no. 2
Number of subjects: 48
Study: 9175396

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg/dose daily for 3 days)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 8248275

Group type: EXPERIMENTAL
Intervention: Primrose oil (n = 7)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fish oil (n = 5)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 18
Study: 2940473

Group type: EXPERIMENTAL
Intervention: Propranolol and primidone
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 18
Study: 31935026

Group type: EXPERIMENTAL
Intervention: Counseling behavioral intervention promoting consumption of 7 or more daily vegetable servings (MEAL intervention; n=237)
Number of subjects: 478

Group type: COMPARATOR
Intervention: Control group receiving written information about diet and prostate cancer (n=241)
Number of subjects: 478
Study: 31828742

Group type: EXPERIMENTAL
Intervention: Hood oxygen delivery system
Number of subjects: 120

Group type: COMPARATOR
Intervention: Oronasal mask oxygen delivery system
Number of subjects: 120
Study: 28533075

Group type: EXPERIMENTAL
Intervention: TENS (20 minutes session)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: LMT (20 minutes session)
Number of subjects: 30
Study: 27487637

Group type: EXPERIMENTAL
Intervention: Bonfils intubation fibrescope
Number of subjects: 44

Group type: COMPARATOR
Intervention: C‐MAC videolaryngoscope
Number of subjects: 44
Study: 25175875

Group type: EXPERIMENTAL
Intervention: Water-based interventions for schistosomiasis control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mass drug administration with praziquantel
Number of subjects: 0
Study: 22246963

Group type: EXPERIMENTAL
Intervention: Computerized prescribing decision support with patient-specific risk estimates
Number of subjects: 5628

Group type: COMPARATOR
Intervention: Commercial drug alerts
Number of subjects: 5628
Study: 19246726

Group type: EXPERIMENTAL
Intervention: PM101 (150 mg)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Intravenous amiodarone (150 mg)
Number of subjects: 88
Study: 17823420

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate, high-fat (LCHF) diet
Number of subjects: 93

Group type: COMPARATOR
Intervention: High-carbohydrate, low-fat (HCLF) diet
Number of subjects: 93
Study: 14747042

Group type: EXPERIMENTAL
Intervention: Estramustine (280 mg tid, days 1 to 5) and docetaxel (70 mg/m2 on day 2) before radical prostatectomy (RP)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Radical prostatectomy (RP) alone
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Neoadjuvant estramustine and docetaxel before RP
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: RP with and without neoadjuvant estramustine and docetaxel
Number of subjects: 700
Study: 10718464

Group type: EXPERIMENTAL
Intervention: nCPAP intervention
Number of subjects: 63

Group type: COMPARATOR
Intervention: Antireflux therapy (nizatidine)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control subjects (AHI <5.0)
Number of subjects: 63
Study: 9177894

Group type: EXPERIMENTAL
Intervention: Trypsin: chymotrypsin (Chymoral forte DS) preparation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 8263885

Group type: EXPERIMENTAL
Intervention: Hydroflumethiazide 50 mg and Reserpine 0.125 mg (H-R)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Chlortalidone 12.5 mg and Atenolol 50 mg (C-A)
Number of subjects: 49
Study: 2939815

Group type: EXPERIMENTAL
Intervention: Subcutaneous catheter irrigated with antibiotic
Number of subjects: 3282

Group type: EXPERIMENTAL
Intervention: Subcutaneous catheter irrigated with saline
Number of subjects: 3282

Group type: EXPERIMENTAL
Intervention: Subcutaneous catheter alone
Number of subjects: 3282

Group type: COMPARATOR
Intervention: Primary closure
Number of subjects: 3282
Study: 31780023

Group type: EXPERIMENTAL
Intervention: Oil pulling therapy with coconut oil
Number of subjects: 29

Group type: COMPARATOR
Intervention: 0.2% chlorhexidine gluconate (CHX)
Number of subjects: 29
Study: 29920852

Group type: COMPARATOR
Intervention: Morphine 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine 1.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine in trapezius muscle
Number of subjects: 0
Study: 27474943

Group type: EXPERIMENTAL
Intervention: Abdominal binder
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control (no abdominal binder)
Number of subjects: 84
Study: 25166443

Group type: EXPERIMENTAL
Intervention: Lidocaine gel (Aqua Touch™) applied immediately before cystoscopy (Group 2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lidocaine gel (Aqua Touch™) applied with a 10-minute clamping before cystoscopy (Group 3)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Liquid glycerine applied immediately before cystoscopy (Group 1)
Number of subjects: 30
Study: 22181580

Group type: EXPERIMENTAL
Intervention: Accurate messages
Number of subjects: 80

Group type: COMPARATOR
Intervention: Inaccurate messages
Number of subjects: 80

Group type: COMPARATOR
Intervention: Neutral messages
Number of subjects: 80

Group type: COMPARATOR
Intervention: No messages
Number of subjects: 80
Study: 19666195

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy + Treatment As Usual (MBCT+TAU)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 60
Study: 18028969

Group type: EXPERIMENTAL
Intervention: FLOTAC technique
Number of subjects: 102

Group type: COMPARATOR
Intervention: Kato‐Katz technique
Number of subjects: 102

Group type: COMPARATOR
Intervention: Ether concentration technique
Number of subjects: 102
Study: 16202291

Group type: EXPERIMENTAL
Intervention: 3 day miconazole (400 mg/d)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 6 day miconazole (400 mg/d)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 7 day miconazole (200 mg/d)
Number of subjects: 300
Study: 12891550

Group type: EXPERIMENTAL
Intervention: Regular milk products (calcium supply, 1100 mg/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo milk products (calcium supply, 60 mg/day)
Number of subjects: 32
Study: 10483927

Group type: EXPERIMENTAL
Intervention: Therapeutic sleep deprivation (TSD) + paroxetine
Number of subjects: 173

Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 173

Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study: 8694086

Group type: EXPERIMENTAL
Intervention: 0.2% dorzolamide
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: 0.7% dorzolamide
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: 2.0% dorzolamide
Number of subjects: 333

Group type: COMPARATOR
Intervention: Placebo (vehicle of dorzolamide)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: 0.7% dorzolamide (one-year extension)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: 2.0% dorzolamide (one-year extension)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: 0.5% timolol (if needed during one-year extension)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Dorzolamide (after 12 months)
Number of subjects: 333
Study: 1831628

Group type: EXPERIMENTAL
Intervention: Ondansetron plus dexamethasone (ondansetron 0.15 mg/kg IV every 2 hours + dexamethasone 20 mg IV single dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ondansetron alone (ondansetron 0.15 mg/kg IV every 2 hours)
Number of subjects: 0
Study: 6807081

Group type: EXPERIMENTAL
Intervention: Valproic acid
Number of subjects: 17
Study: 31750145

Group type: EXPERIMENTAL
Intervention: Temporalis fascia
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Conchal cartilage
Number of subjects: 40
Study: 28757439

Group type: EXPERIMENTAL
Intervention: Robotic simulator assessment metrics (dV‐Trainer and da Vinci Skills Simulator)
Number of subjects: 74

Group type: COMPARATOR
Intervention: GEARS evaluation scores
Number of subjects: 74
Study: 25649640

Group type: EXPERIMENTAL
Intervention: Avizor Alvera® (study solution)
Number of subjects: 20

Group type: COMPARATOR
Intervention: All Clean Soft® (control solution)
Number of subjects: 20
Study: 24819510

Group type: EXPERIMENTAL
Intervention: Low-molecular weight heparin (LMWH) along with physical measures (compression stockings)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Physical measures (compression stockings) only
Number of subjects: 74
Study: 21849647

Group type: EXPERIMENTAL
Intervention: Interferon β‐1b (250 μg, subcutaneously every other day for 2 years)
Number of subjects: 292
Study: 19139851

Group type: EXPERIMENTAL
Intervention: risperidone 6 mg/day
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: haloperidol 20 mg/day
Number of subjects: 78

Group type: COMPARATOR
Intervention: Medication-free SCH patients
Number of subjects: 78
Study: 17456248

Group type: EXPERIMENTAL
Intervention: Multivitamin tablets (n 28)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Fish oil capsules (n 27)
Number of subjects: 55
Study: 12841346

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (120 mg/day)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control (B vitamin group B)
Number of subjects: 144
Study: 10543679

Group type: EXPERIMENTAL
Intervention: Sequential transdermal progesterone with continuous transdermal oestrogen
Number of subjects: 0
Study: 9345379

Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1861000

Group type: EXPERIMENTAL
Intervention: I tones with periods close to p (± 3% or 6% apart)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: I tones with same harmonic content as the test tones
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: I tones with very different harmonic content
Number of subjects: 0
Study: 7044462

Group type: EXPERIMENTAL
Intervention: Pre-operative pelvic radiotherapy (4000 rads) and elective radical cystectomy
Number of subjects: 189

Group type: COMPARATOR
Intervention: Radical radiotherapy (4000 rads plus 2000 rads boost)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Pre-operative pelvic radiotherapy and cystectomy in patients aged less than 60
Number of subjects: 189

Group type: COMPARATOR
Intervention: Radical radiotherapy in patients aged less than 60
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Pre-operative pelvic radiotherapy and cystectomy in males
Number of subjects: 189

Group type: COMPARATOR
Intervention: Radical radiotherapy in males
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Pre-operative pelvic radiotherapy
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Elective cystectomy when lymph nodes are not involved
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Elective cystectomy when lymph nodes are positive
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Salvage cystectomy for local tumour recurrence following radical radiotherapy
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Patients with pelvic metastases
Number of subjects: 189
Study: 31027120

Group type: EXPERIMENTAL
Intervention: Submucosal bupivacaine injection
Number of subjects: 86

Group type: COMPARATOR
Intervention: Conventional solution
Number of subjects: 86
Study: 27779568

Group type: EXPERIMENTAL
Intervention: Oral conjugated estrogens (o‐CEE) 0.45 mg (n=230)
Number of subjects: 727

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (t‐E2) 50 μg (n=225)
Number of subjects: 727

Group type: COMPARATOR
Intervention: Placebo (PBO) (n=275)
Number of subjects: 727
Study: 26720504

Group type: EXPERIMENTAL
Intervention: Housing First (HF)
Number of subjects: 2148

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 2148
Study: 22692123

Group type: EXPERIMENTAL
Intervention: HImax (1 set of 10-12 repetitions at 80% 1RM)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: LOmax (1 set of 10-12 repetitions at 40% 1RM, preceded by 60 repetitions at 20-25% 1RM)
Number of subjects: 36

Group type: COMPARATOR
Intervention: LO (1 set of 10-12 repetitions at 40% 1RM, no maximal effort)
Number of subjects: 36
Study: 21448726

Group type: EXPERIMENTAL
Intervention: Pouch-double tract (PDT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional Roux-en-Y reconstruction (RY)
Number of subjects: 29
Study: 19195512

Group type: EXPERIMENTAL
Intervention: Probucol (500 mg orally twice daily)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Probucol
Number of subjects: 205
Study: 17035452

Group type: EXPERIMENTAL
Intervention: CAP-related symptoms assessed using the CAP score
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: HRQL assessed using the SF-36 questionnaire at 18 months
Number of subjects: 102
Study: 15190700

Group type: EXPERIMENTAL
Intervention: Geometric model of compressed individual color spaces
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 0
Study: 10353511

Group type: EXPERIMENTAL
Intervention: Ceftriaxone, 50 mg/kg (single intramuscular dose)
Number of subjects: 513

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate, 80 mg/kg/day of amoxicillin: 10 mg/kg/day of clavulanate for 10 days
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 513

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 513
Study: 8599787

Group type: EXPERIMENTAL
Intervention: Ketorolac (intramuscularly)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Indomethacin (rectally)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 1770473

Group type: EXPERIMENTAL
Intervention: Combined lipid-lowering and antihypertensive treatment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 36
Study: 7054311

Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride pretreatment
Number of subjects: 0
Study: 30155904

Group type: EXPERIMENTAL
Intervention: Sun protection advice and equipment
Number of subjects: 98

Group type: COMPARATOR
Intervention: No sun protection advice and equipment (Control)
Number of subjects: 98
Study: 29222893

Group type: EXPERIMENTAL
Intervention: Krill oil (KO) - 5 capsules (907 mg LC n-3 PUFA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) - 5 capsules (1441 mg LC n-3 PUFA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Olive oil (OO) - control
Number of subjects: 10
Study: 26366639

Group type: EXPERIMENTAL
Intervention: Elevated symptoms of depression (BDI‐II)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Elevated symptoms of distress (GHQ)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Anxiety (Spielberger Anxiety Inventory)
Number of subjects: 132
Study: 24523436

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) applied to the collapsed right lung
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no CPAP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (CPAP and Control)
Number of subjects: 30
Study: 22444237

Group type: EXPERIMENTAL
Intervention: Preoperative carbohydrate treatment (PCT) - 600 ml of a carbohydrate-based drink (ONS, Fresenuis Kabi, 50 g carbohydrate, 15 g glutamine and antioxidants/300 ml)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo - 600 ml of a carbohydrate-free drink (0 g carbohydrate)
Number of subjects: 30
Study: 20609131

Group type: EXPERIMENTAL
Intervention: 800 mg IV-ibuprofen every 6 hours
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 17907107

Group type: EXPERIMENTAL
Intervention: Tesaglitazar 0.25 mg
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Tesaglitazar 0.5 mg
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Tesaglitazar 1 mg
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Tesaglitazar (all doses)
Number of subjects: 222
Study: 16045858

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30

Group type: COMPARATOR
Intervention: ACTH stimulation test
Number of subjects: 30
Study: 12239480

Group type: EXPERIMENTAL
Intervention: Linkmax (self-etching adhesive and its respective cement)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: RelyX ARC (conventionally etched adhesive and its cement)
Number of subjects: 22

Group type: COMPARATOR
Intervention: No treatment (negative control)
Number of subjects: 22
Study: 10570375

Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% gel pretreatment 3 times per week for 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thin application of tazarotene gel immediately before phototherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thick application of tazarotene gel immediately before phototherapy
Number of subjects: 0
Study: 8635058

Group type: COMPARATOR
Intervention: Conventional therapy (Group A)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Intensive therapy (Group B)
Number of subjects: 66
Study: 2127226

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (400 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30841930

Group type: EXPERIMENTAL
Intervention: NO-FEAR Airlines (self-applied)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: NO-FEAR Airlines (with therapist guidance)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: NO-FEAR Airlines (both methods)
Number of subjects: 69
Study: 28152673

Group type: EXPERIMENTAL
Intervention: Eccentric-overload training (EOT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control
Number of subjects: 18
Study: 25177768

Group type: EXPERIMENTAL
Intervention: Laparoscopic ureterolithotomy (LU)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Ureteroscopic lithotripsy (URS)
Number of subjects: 110
Study: 23530969

Group type: EXPERIMENTAL
Intervention: HQK-1001 (20 mg/kg per day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 22085316

Group type: EXPERIMENTAL
Intervention: Atorvastatin, 80 mg daily
Number of subjects: 1039

Group type: EXPERIMENTAL
Intervention: Rosuvastatin, 40 mg daily
Number of subjects: 1039
Study: 19088267

Group type: EXPERIMENTAL
Intervention: AMG 487 at 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AMG 487 at higher doses (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AMG 487
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: M2 (metabolite of AMG 487)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: M2
Number of subjects: 0
Study: 18193495

Group type: EXPERIMENTAL
Intervention: Carraguard gel applied vaginally once per day for 14 days (women)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Carraguard gel applied directly to the penis once per day for 7 days (men)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Methylcellulose placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: No product (control)
Number of subjects: 60
Study: 15586635

Group type: EXPERIMENTAL
Intervention: 123I‐FPCIT SPECT in NC
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 123I‐FPCIT SPECT in PD
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 123I‐FPCIT SPECT in NC with subdivided ROI
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 123I‐FPCIT SPECT in PD with subdivided ROI
Number of subjects: 16
Study: 11528360

Group type: EXPERIMENTAL
Intervention: Red clover isoflavones (approximately 50 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9779530

Group type: EXPERIMENTAL
Intervention: Lidocaine injection
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline injection
Number of subjects: 80
Study: 7522899

Group type: EXPERIMENTAL
Intervention: Autologous transplantation of CD34-positive cells
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Enrichment of CD34+ cells from PBPC collections
Number of subjects: 66
Study: 2901993

Group type: EXPERIMENTAL
Intervention: Acrivastine (BW 825C; 8 mg 3 times daily)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cyproheptadine (4 mg 3 times daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 30808264

Group type: EXPERIMENTAL
Intervention: Working memory training interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (preferably active)
Number of subjects: 0
Study: 29715448

Group type: EXPERIMENTAL
Intervention: Surgical safety checklist
Number of subjects: 80

Group type: COMPARATOR
Intervention: No checklist (Control)
Number of subjects: 80
Study: 29166928

Group type: EXPERIMENTAL
Intervention: Iron and folic acid supplementation
Number of subjects: 1954

Group type: COMPARATOR
Intervention: Folic acid alone (Control)
Number of subjects: 1954
Study: 26600645

Group type: EXPERIMENTAL
Intervention: Aqueous extract of Hibiscus sabdariffa (150 mg/kg/day)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Lisinopril (10 mg once daily)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo (150 mg/kg/day)
Number of subjects: 78
Study: 23786757

Group type: EXPERIMENTAL
Intervention: TPF induction chemotherapy
Number of subjects: 232

Group type: COMPARATOR
Intervention: High Annexin A1 expression
Number of subjects: 232
Study: 20096534

Group type: EXPERIMENTAL
Intervention: RT + TME
Number of subjects: 1417

Group type: COMPARATOR
Intervention: TME alone
Number of subjects: 1417

Group type: EXPERIMENTAL
Intervention: APR surgery
Number of subjects: 1417

Group type: EXPERIMENTAL
Intervention: Negative circumferential resection margin
Number of subjects: 1417

Group type: EXPERIMENTAL
Intervention: Advanced tumors
Number of subjects: 1417

Group type: EXPERIMENTAL
Intervention: Lateral LR
Number of subjects: 1417

Group type: EXPERIMENTAL
Intervention: Anterior or anastomotic LRs
Number of subjects: 1417
Study: 17973330

Group type: EXPERIMENTAL
Intervention: Active deep brain stimulation (DBS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study: 16644434

Group type: EXPERIMENTAL
Intervention: Increased preload by rapid infusion of 30 mL/kg of saline over 15 minutes
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Increased afterload simulated in a controlled hypoxic environment (fractional concentration of oxygen in inspired gas = 12.3%)
Number of subjects: 17